Indian Journal of Medical Biochemistry

Register      Login

VOLUME 24 , ISSUE 1 ( January-April, 2020 ) > List of Articles


Evanescence Meets Elegance: Story of Invisible Sweet Marker

Satish Ramanathan, Srinivas N Chakravarthy, S Kavitha

Citation Information : Ramanathan S, Chakravarthy SN, Kavitha S. Evanescence Meets Elegance: Story of Invisible Sweet Marker. Indian J Med Biochem 2020; 24 (1):37-41.

DOI: 10.5005/jp-journals-10054-0132

License: CC BY-NC 4.0

Published Online: 03-11-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Aim: To explore the interference of a hemoglobin E on glycated hemoglobin (HbA1c) measurement on two methodologies including high performance liquid chromatography (HPLC) and immunoassay. Background: HbA1c is an invincible analyte in modern laboratory medicine era. The role of HbA1c in diabetes mellitus has expanded from prognosis to diagnosis of diabetes. Hence, it becomes an essential responsibility of the medical testing laboratories to deliver quality results to the patients. The quality of a result is determined by several factors. One essential determinant of the quality of an analyte in a clinical laboratory is the choice of method of testing. HbA1c has various standardized methods of measurement, each of it having its own advantages and limitations. One significant limitation is interference from abnormal hemoglobins. Case description: In our case report, we have tried to explore the interference of hemoglobin E on HbA1c measurement on two methodologies including HPLC and immunoassay. In our case scenario, HbA1c immunoassay could produce a reliable HbA1c result, while HPLC was significantly being interfered by the hemoglobin variant. Conclusion: With respect to HbA1c, each method has its own advantages and limitations. It is the responsibility of the laboratories to understand, adopt, and optimally utilize these methods based on the needs. Clinical significance: HbA1c is the gold standard investigation for monitoring patients with diabetes mellitus. National Glycohemoglobin Standardization Program (NGSP) provides traceability and improvement in standardization of methods used for A1C measurement. Each method has its own limitations; the most significant from the clinical significance point of view is being interfered by the abnormal hemoglobins. Hence, each laboratory must understand the strengths and limitations of the available methods in their premises and hold the responsibility for reporting clinically relevant results to its patients.

PDF Share
  2. Rhea JM, Molinaro R. Pathology consultation on HbA1c methods and interferences. Am J Clin Pathol 2014;141(1):5–16. DOI: 10.1309/AJCPQ23GTTMLAEVL.
  3. Simpson WG, Twomey PJ. Reflective testing. J Clin Pathol Reflective testing 2004;57(3):239–240. DOI: 10.1136/jcp.2003.011668.
  4. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. BJH 2010;149(1):35–49. DOI: 10.1111/j.1365-2141.2009.08054.x.
  5. Mosca A, Paleari R, Ivaldi G, et al. The role of haemoglobin A2 testing in the diagnosis of thalassaemias and related haemoglobinopathies. J Clin Pathol 2009;62(1):13–17. DOI: 10.1136/jcp.2008.056945.
  6. Joutovsky A, Nesic HJ, Nardi MA. HPLC retention time as a diagnostic tool for hemoglobin variants and hemoglobinopathies: a study of 60000 samples in a clinical diagnostic laboratory. Clin Chem 2004;50(10):1736–1747. DOI: 10.1373/clinchem.2004.034991.
  7. Wakeman L, Munro R, Russell C, et al. New reference ranges in haematology for healthy adults using the modern Sysmex XE-2100 automated analyser. Blood 2005;106(11):3740–3745. DOI: 10.1182/blood.V106.11.3740.3740.
  8. Vichinsky E. Hemoglobin E syndromes. Hematol 2007(1):79–83. DOI: 10.1182/asheducation-2007.1.79.
  9. HbA1c kit insert. Vitros. Pub No. J55871_EN, version 4:1-18.14.
  10. Yedla N, Kuchav MS, Mithal A. Hemoglobin E disease and glycosylated hemoglobin. Indian J Endocrinol Metab 2015;19(5):683–685. DOI: 10.4103/2230-8210.163211.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.